VIENNA, AT – May 31, 2017. DePuy Synthes, part of the Johnson & Johnson Family of Companies, today announced new ATTUNE® Knee implant survivorship data based on an Implant Summary Report obtained from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR). The independent analysis of 10,605 ATTUNE Knee implantations, showed that the cumulative revision rate for the ATTUNE Knee is 1.3% at four years (98.7% implant survivorship at four years), compares favorably to the 1.9% cumulative revision rate (98.1% implant survivorship at four years) for the overall class of total knee replacement.1
Of the 10,605 ATTUNE Knees included in the analysis from the NJR, 46 required revision. Based on a separate analysis, the report concluded that 63 ATTUNE Knee revisions would be expected at four years – a difference that was statistically significant (p<0.05).1 The expected number of ATTUNE Knee revisions was calculated by the NJR based on duration of implantation, age group, gender and indications.
DePuy Synthes announced the four-year data in Vienna, coinciding with the 18th European Federation of the National Associations of Orthopaedics and Traumatology (EFORT) Congress. The full analysis, including a breakdown of the reasons for revision, is available on www.ProvingthePromise.com and can be accessed here .
“This most recent analysis adds to the body of evidence on the positive performance of the ATTUNE Knee,” said Joshua Bridgens, DePuy Synthes Franchise Medical Director. “The information and data in this analysis, such as reasons for revision and preliminary findings on patient-reported outcomes, continue to validate the design principles and our expectations for the clinical performance of the ATTUNE Knee.”
NJR publishes an annual report including 1, 3 and 5-year outcome data; however, additional survivorship data is now also available more frequently to manufacturers who subscribe to the NJR’s Implant Summary Report service.
DePuy Synthes is committed to the continued evaluation of outcomes through its comprehensive ATTUNE Knee Evidence Generation Program that, in addition to national joint registries, gathers information frominvestigator-initiated studies, independent studies and company initiated studies. ATTUNE Knee clinical evidence to date is available on www.ProvingthePromise.com
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive portfolios of orthopaedic solutions in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com .
The third party trademarks used herein are the trademarks of their respective owners.
©Johnson & Johnson Medical Limited. 2017. All rights reserved.
Registered Office: Johnson & Johnson Medical Limited, PO BOX 1988, Simpson Parkway, Livingston, West Lothian, EH54 0AB, United Kingdom. Incorporated and registered in Scotland under company number SC132162
1 National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Implant Summary Report for DePuy ATTUNE CR and ATTUNE PS. NJR Database extract April 7, 2017, pages 1-17. Licensed for use until April 19, 2018. Available at www.ProvingthePromise.com
The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership (“HQIP”) and/or the National Joint Registry (“NJR”) take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources, and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.